We will use cookies and other information to optimize your experience. By continuing to browse, you consent to our use. For details, please read
Privacy Policy
×
Gongwin Biopharm Co., Ltd.
Language
繁體中文
English
About Us
Company Profile
Company presentation
History
Our Team
Partnerships – Human Indication
Partnerships – Animal Drugs
News&Media
Press Release
Latest Updates
Events
Pipeline
Products
Product Features
DM
PTS302 NSCLC-SMAO
Medical column
Treatment Result or Case
Pipeline development milestones
PTS100 HCC
Medical column
Treatment Result or Case
Clinical Trials
Pipeline development milestones
PTS-02 ACC
Medical column
Treatment Result or Case
Pipeline development milestones
PTS500 MPE
Medical column
Treatment Result or Case
Pipeline development milestones
Anti-tumor drug for canine use
DM
Introduction
Introduction of PTS Trial Drugs and Core Technology of "Minimally Invasive Targeted Tumor Ablation"
History of Animal Clinical Trials
Case Acceptance Indications
Superficial malignant tumor in canine
Malignant melanoma of the canine
Lipoma of the canine and feline
Malignant bladder tumor of the canine and feline
Video
R & D
Core Technology
Mechanism of Action
R & D Center
Published Paper
Investors
Financial information
Company annual report
Financial report
Monthly revenue
Legal person briefing
Corporate Governance
Corporate governance structure
Board of Directors
Committee
Internal audit
Company regulations
Other corporate governance information
Shareholder area
Shareholders' meeting
Dividend distribution
Material message
Stock price message
Investor Relations Contact Window
Stock agency
Interest relationship
Interested parties communicate with the company
Youtube
Contact
Home
News&Media
Press Release
24
2022.02
Pet Medical Care
25
2021.05
Gongwin’s Compassionate treatment is app...
24
2021.05
Gongwin-KY Adopted Compassionate Treatme...
02
2021.02
Gongwin-KY Completed Case Acceptance for...
13
2020.11
Gongwin-KY’s endeavors in furry baby can...
08
2020.07
Zhong Nanshan led Gongwin-KY, the pionee...
1
2
3
1
2
3
繁體中文
English
Language
繁體中文
English
About Us
Company Profile
Company presentation
History
Our Team
Partnerships – Human Indication
Partnerships – Animal Drugs
News&Media
Press Release
Latest Updates
Events
Pipeline
Products
Product Features
DM
PTS302 NSCLC-SMAO
Medical column
Treatment Result or Case
Pipeline development milestones
PTS100 HCC
Medical column
Treatment Result or Case
Clinical Trials
Pipeline development milestones
PTS-02 ACC
Medical column
Treatment Result or Case
Pipeline development milestones
PTS500 MPE
Medical column
Treatment Result or Case
Pipeline development milestones
Anti-tumor drug for canine use
DM
Introduction
Introduction of PTS Trial Drugs and Core Technology of "Minimally Invasive Targeted Tumor Ablation"
History of Animal Clinical Trials
Case Acceptance Indications
Superficial malignant tumor in canine
Malignant melanoma of the canine
Lipoma of the canine and feline
Malignant bladder tumor of the canine and feline
Video
R & D
Core Technology
Mechanism of Action
R & D Center
Published Paper
Investors
Financial information
Company annual report
Financial report
Monthly revenue
Legal person briefing
Corporate Governance
Corporate governance structure
Board of Directors
Committee
Internal audit
Company regulations
Other corporate governance information
Shareholder area
Shareholders' meeting
Dividend distribution
Material message
Stock price message
Investor Relations Contact Window
Stock agency
Interest relationship
Interested parties communicate with the company
Youtube
Contact
